Experimental Drug Slows Decline among Alzheimer’s Patients
Drugmakers Biogen and Eisai say their experimental drug lecanemab slowed the progress of Alzheimer’s disease in a large human study the companies did. The results could mean a rare victory in a field filled with failed experiments to find an effective treatment for the disease.